Functionalised liposomes and use thereof to produce cosmetic or pharmaceutical compositions for the treatment of psoriasis and vitiligo

Functionalized liposomes with a CXCL10-derived peptide specifically target CXCR3B receptors in psoriasis and vitiligo, providing precise and effective delivery of active ingredients to affected areas, addressing the limitations of current treatments by enhancing specificity and reducing adverse effects.

WO2024261352A1PCT designated stage expired Publication Date: 2024-12-26DERMOPARTNERS
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/ES2023/070402
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-06-20
Publication Date
2024-12-26

AI Technical Summary

Technical Problem

Current treatments for psoriasis and vitiligo lack specificity and efficacy in targeting affected skin areas, often resulting in non-specific delivery and potential long-term adverse effects.

Method used

Functionalized liposomes with a peptide affinity for the CXCR3B receptor are used to encapsulate active ingredients, allowing precise targeting and delivery to affected areas by leveraging the receptor's overexpression in these conditions, utilizing a peptide sequence derived from CXCL10 and attached via click chemistry to maleimide-containing phospholipids.

Benefits of technology

The solution enables targeted and specific delivery of active ingredients to affected skin areas, enhancing treatment effectiveness while minimizing risks of adverse effects by exploiting the increased receptor expression in psoriasis and vitiligo, thereby improving the therapeutic outcomes for these autoimmune skin disorders.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to liposomes functionalised with a peptide with affinity for the receptor CXCR3-B, and to the use of same to obtain pharmaceutical or cosmetic preparations for the treatment of psoriasis and vitiligo.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] DESCRIPTION

[0002] Functionalized liposomes and their use in obtaining cosmetic or pharmaceutical compositions for the treatment of psoriasis and vitiligo

[0003] Technical sector

[0004] The object of the present invention has application in the field of the medical, pharmaceutical and cosmetic industries, since it involves liposomes and their use in the preparation of compositions used to treat skin disorders in cases of psoriasis and vitiligo.

[0005] Background of the invention

[0006] Among the background of the invention we can find patent DE4021084 which refers to “Topical fumarate compound containing liposomes that improve bioavailability especially for the treatment of psoriasis, contain liposomal structure, alcohol, stabilizer and fumaric acid (derivative) and are stable and non-irritating”, however in this case liposomes functionalized with a peptide that has affinity for cell receptors that are overexpressed in cases of psoriasis are not used.

[0007] Another background to cite is patent LIS2013053319 (A1) referring to “Chemokine-derived peptides and uses for chronic wound and angiogenesis inhibition treatments” in which peptides that have activity against the CXCR3 receptor are described and the invention relates to peptides that have angiogenesis inhibition activity that may be useful in the treatment of diseases associated with excessive angiogenesis, including tumorigenic diseases such as cancers, genes to encode them and methods and uses thereof in the treatment of such diseases. In this case, the use of these peptides is for their direct effect for the treatment of these diseases, unlike the present invention in which the use of the peptides is to bind them to liposomes with certain active ingredients and promote the effect of these active ingredients in cases of psoriasis and vitiligo.

[0008] Description of the invention The present invention relates to liposomes functionalized with a peptide with affinity for the CXCR3B receptor and the use thereof in pharmaceutical or cosmetic preparations for the topical treatment of psoriasis and vitiligo.

[0009] Liposomes are nanosized vesicles. They are capable of encapsulating both hydrophilic and hydrophobic compounds, improving their solubility and stability. Furthermore, they have a lipid layer similar to that of cell membranes, which makes them biocompatible and gives them good affinity with the skin, promoting penetration. Therefore, these systems are used to transport active ingredients through the skin, improving their effectiveness. Additionally, liposomes are made of phospholipids, whose qualities are also useful in the treatment of skin conditions: epithelializing (they repair the damaged stratum corneum, improving the skin's barrier function), anti-inflammatory, bactericidal, sebum-regulating, and whitening (they even out skin tone). Furthermore, ligands can be conjugated to the outer surface of liposomes, which have affinity for a specific cell involved in a particular pathology.This allows liposomes loaded with active ingredients effective for this pathology to be directed to the affected areas and act precisely on them, thereby increasing the effectiveness and specificity of the treatment.

[0010] In this case, a peptide with affinity for the chemokine receptor 3 (CXCR3) was chosen as the ligand. Chemokines are a group of low molecular weight polypeptides containing 60-100 amino acids that, together with their receptors, regulate inflammatory processes. Chemokine ligand 10 (CXCL10) is secreted by multiple cell types, including lymphocytes, monocytes, keratinocytes, fibroblasts, and endothelial cells in response to interferon (IFN)-γ and TNFα. CXCL10 has angiostatic properties and recruits leukocytes such as T cells, eosinophils, monocytes, and NK cells to sites of inflammation through interaction with its receptor, CXCR3. This receptor is expressed on various cell types, but preferentially on monocytes, Th1 T cells, CD8 T cells, NKT cells, NK cells, dendritic cells, and some cancer cells.

[0011] Vitiligo is a skin pigmentation disorder that affects approximately 1–2% of the population, with no predilection for age, sex, or race. It is characterized by the appearance of achromatic macules, whose typical histopathological substrate is the absence of identifiable melanocytes. Several factors contribute to the development of vitiligo's pathophysiology, including genetic, environmental, and immunological factors. The interaction between these factors culminates in autoimmunity as the main factor in the pathogenesis of the disease, exerted through melanocyte-specific autoreactive cytotoxic CD8 T lymphocytes guided by IFNγ. Vitiligo is, therefore, an autoimmune disease. Autoimmune diseases are those in which the immune system recognizes its own structures as foreign, causing their destruction and resulting in disease.The initial triggering events that lead to immune system activation in vitiligo arise from a combination of intrinsic melanocyte defects and exposure to specific environmental factors, such as ultraviolet light or chemicals, that increase oxidative stress in these cells. In the present invention, the CXCR3B receptor was chosen as the target since it has been shown that, in vitiligo skin, CXCR3B receptor expression is increased in both immune cells and melanocytes.

[0012] On the other hand, psoriasis is a chronic disease characterized by patchy, reddish plaques on the skin that are inflamed and scaly. This is due to hyperproliferation of keratinocytes, leading to increased epidermal turnover and infiltration of immune cells into the dermis and epidermis. Individuals with this disease, who represent 1-5% of the global population, suffer from symptoms such as itching and pain, but also skin lesions, especially in exposed areas such as the face, hands, and nails, which can have a significant impact on the patient's quality of life. Furthermore, it often coexists with comorbidities such as psoriatic arthritis, uveitis, psychiatric disorders, metabolic disorders, and cardiovascular disease. It has an unknown etiology, is incurable, and is relapsing, occurring either in flares or constantly due to triggering factors.Because epidermal changes are so prominent, it was assumed for years that psoriasis was a disease of keratinocytes. However, psoriasis is actually a T-cell-mediated autoimmune disease. In this disease, chemokines are involved in both the recruitment and activation of T cells, macrophages, and neutrophils at the site of psoriatic inflammation. Specifically, CXCR3 and associated chemokine ligands constitute a very important chemotactic response to interferon-mediated inflammation. Therefore, immune system cells (epidermal T cells, plasmacytoid dendritic cells, and NK cells) express CXCR3. In summary, in vitiligo skin, the CXCR3B receptor is overexpressed in melanocytes, whereas in psoriasis, immune system cells, such as epidermal T cells, express CXCR3.Consequently, the liposomes of the present invention, functionalized with a specific ligand for this receptor, will act specifically on cells affected by vitiligo and psoriasis, releasing the encapsulated active ingredients there, and not on adjacent cells. This will be an effective treatment, with cell specificity and a low risk of long-term adverse effects.

[0013] Finally, to achieve this affinity for the CXCR3B receptor, a fragment of the chemokine CXCL10, a ligand of said receptor, was chosen as the functionalizing peptide. The specific amino acid sequence is CPESKAIKNLLKAVSKEMSKRSP (SEQ ID NO 1). This sequence is partially described in patent US2013053319 (A1) as PESKAIKNLLKAVSKEMSKRSP (SEQ ID NO 2), with that of the present invention being differentiated by the incorporation of a cysteine ​​at the N-terminus. The peptide is covalently bound to the liposomes once formed by a click chemistry reaction between maleimide groups exposed on the outside of the liposome and the thiol group at the end of the peptide. To promote subsequent binding of the peptide to its target receptor, maleimide-containing phospholipids have a polyethylene glycol spacer group between the phospholipid and the maleimide.

[0014] Preferred realization

[0015] In a preferred embodiment, the functionalized liposomes for obtaining cosmetic or pharmaceutical compositions comprise: a) at least one peptide with the sequence CPESKAIKNLLKAVSKEMSKRSP SEQ ID NO: 1 linked by the N-terminal end; ab) a liposome consisting of maleimide groups (Mal) on its exterior due to the incorporation of DSPE-PEG2000-Mal in the preparation of said system, and containing c) at least one pharmaceutical or cosmetic active ingredient for the treatment of psoriasis and / or vitiligo. The functionalized liposomes contain the peptide with the sequence SEQ ID NO: 1 which coincides with the peptide with the sequence SEQ ID NO: 2 except for the presence at the beginning of the sequence of a cysteine ​​necessary for its anchoring in the maleimide on the exterior of the liposome.

[0016] Functionalized liposomes may have a peptide anchored to the liposome that is different from the sequence SEQ ID NO: 1 but that matches in sequence 80% of the amino acids from position 2 to 23 of the sequence SEQ ID NO: 1.

[0017] From these liposomes, a pharmaceutical or cosmetic composition for topical use is prepared, comprising the functionalized liposomes described above as an active ingredient, in combination with one or more pharmaceutically or cosmetically acceptable excipients or adjuvants that would be used topically for the treatment of psoriasis and vitiligo.

[0018] An example of a pharmaceutical or cosmetic composition containing these functionalized liposomes and with the weight percentages of its components would be the following:

[0019] Water: 75-100%

[0020] Phosphatidylcholine: 5-10%

[0021] DSPE-PEG-Mal: 0.1-2%

[0022] Alcohol: 1-5%

[0023] Polysorbate 20: 1-5%

[0024] Phenoxyethanol: 0.1-1%

[0025] Glycerin: 0.1-1%

[0026] Peptide: 0.1-4%

[0027] Active ingredient: 0-5%

[0028] Once the nature of the invention has been sufficiently described, as well as a preferred embodiment example, it is stated for the appropriate purposes that the components described may be modified, as long as this does not entail an alteration of the essential characteristics of the invention claimed below.

Claims

CLAIMS 1.- Functionalized liposomes for obtaining cosmetic or pharmaceutical compositions comprising: a) at least one peptide with the sequence SEQ ID NO: 1 linked by the N-terminal end ab) a liposome containing c) at least one active pharmaceutical or cosmetic ingredient 2.- Functionalized liposomes according to claim 1, wherein one of the components of the liposome is DSPE-PEG-Mal, such that the peptide is covalently linked to the maleimide groups (Mal) located on the outside of the liposome. 3.- Functionalized liposomes according to claim 1, where the peptide with the sequence SEQ ID NO: 1 coincides with the peptide with the sequence SEQ ID NO: 2 except for the presence at the beginning of the sequence of a cysteine necessary for its anchoring to the outside of the liposome. 4.- Functionalized liposomes according to claims 1 and 3, where the peptide anchored to the liposome is different from that of the sequence SEQ ID NO: 1 but which coincides in its sequence with 80% of the amino acids from position 2 to 23 of the sequence SEQ ID NO:

1. 5.- Pharmaceutical or cosmetic composition for topical use comprising functionalized liposomes, as defined in claims 1-4, as an active ingredient, in combination with one or more pharmaceutically or cosmetically acceptable excipients or adjuvants. 6.- Use of the pharmaceutical or cosmetic composition of claim 5 for obtaining cosmetic or pharmaceutical compositions for the treatment of psoriasis and vitiligo. SUBSTITUTE SHEET (RULE 26)

Citation Information

Patent Citations

  • Fumarate topical compsn. contg. liposome(s) improving bio-availability - esp. for treating psoriasis, contain liposomal structure, alcohol, stabiliser and fumaric acid (deriv.) and are stable and non irritant

    DE4021084C1

  • Chemokine derived peptides and uses for chronic wound and angiogenesis inhibition treatments

    US20130053319A1

  • Small peptide compositions and uses thereof

    US20190298802A1

  • Gamma polyglutamated pemetrexed and uses thereof

    US20210161899A1

  • Interferon-inducible protein 10 is a potent inhibitor of angiogenesis

    US5994292A